Teva Shows Its Big Pharma Clout With $1.5bn Sanofi Deal
Israeli Firm Stepping Up Investments In Branded Space, Under CEO Francis
Teva has wrapped up an earlier deal with Sanofi that will see the French giant take command of its novel TL1A inhibitor currently in a Phase IIb study for ulcerative colitis and Crohn’s disease.
You may also be interested in...
As part of a Generics Bulletin series focusing on some of the industry’s biggest players, we look at the changing landscape at Teva in 2023, spearheaded by the appointment of its CEO Richard Francis.
Biopharma executives in Israel rely on their global footprint and a 'culture of resilience'.
Plus deals involving Bristol Myers Squibb/Avidity, Aexon/NLS, Boehringer Ingelheim/Phenomic AI, AnaptysBio/Centessa and Biodexa/Adhera/Melior.